Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Nexviadyme 100 mg powder for concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
avalglucosidase alfa
Company:  
SANOFI See contact details
ATC code: 
A16AB22
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 01 Feb 2024

{equilateral_black_triangle} This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

{pdf} View or print the patient leaflet as PDF

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PLGB 04425/0893.

{printer} Print patient leaflet as text only

Nexviadyme 100 mg powder for concentrate for solution for infusion

Package leaflet: Information for the patient

Nexviadyme 100 mg

powder for concentrate for solution for infusion

avalglucosidase alfa

Is this leaflet hard to see or read? Phone 0800 035 2525 for help.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Nexviadyme is and what it is used for
2. What you need to know before you are given Nexviadyme
3. How Nexviadyme is given
4. Possible side effects
5. How to store Nexviadyme
6. Contents of the pack and other information

1. What Nexviadyme is and what it is used for
What Nexviadyme is

Nexviadyme contains an enzyme called avalglucosidase alfa – it is a copy of the natural enzyme called acid alpha-glucosidase (GAA) that is lacking in people with Pompe disease.

What Nexviadyme is used for

Nexviadyme is used to treat people of all ages who have Pompe disease.

People with Pompe disease have low levels of the enzyme acid alpha-glucosidase (GAA). This enzyme helps control levels of glycogen (a type of carbohydrate) in the body. Glycogen provides the body with energy, but in Pompe disease high levels of glycogen build up in different muscles and damages them. The medicine replaces the missing enzyme so that the body can reduce the build-up of glycogen.

2. What you need to know before you are given Nexviadyme
Do not use Nexviadyme

If you have had life-threatening allergic (hypersensitive) reactions to avalglucosidase alfa or any of the other ingredients of this medicine (listed in section 6) and these reactions occurred again after stopping and restarting the medicine.

Warnings and precautions

Talk to your doctor or pharmacist or nurse before using Nexviadyme

Speak to your doctor immediately if treatment with Nexviadyme causes:

  • allergic reactions, including anaphylaxis (a severe allergic reaction) – see under ‘Possible side effects’, below for symptoms
  • infusion-associated reaction while you are receiving the medicine or in the few hours afterwards – see under ‘Possible side effects’, below for symptoms

Also tell your doctor if you have swelling in your legs or widespread swelling of your body. Your doctor will decide if your Nexviadyme infusion should stop and the doctor will give you appropriate medical treatment. Your doctor will also decide if you can continue receiving avalglucosidase alfa.

Other medicines and Nexviadyme

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Pregnancy and breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. There is no information about the use of Nexviadyme in pregnant women. You must not receive Nexviadyme during pregnancy unless your doctor specifically recommends it. You and your doctor should decide if you can use Nexviadyme if you are breast-feeding.

Driving and using machines

Nexviadyme may have a minor effect on the ability to drive and use machines. Because dizziness, low blood pressure and sleepiness can occur as infusion-associated reactions, this may affect the ability to drive and use machines on the day of the infusion.

3. How Nexviadyme is given

Nexviadyme will be given to you under the supervision of a health care professional who is experienced in the treatment of Pompe disease.

You may be given other medicines before you receive Nexviadyme, to reduce some side effects. Such medicines include an antihistamine, a steroid and a medicine (such as paracetamol) to reduce fever.

The dose of Nexviadyme is based on your weight and will be given to you once every 2 weeks.

  • The recommended dose of Nexviadyme is 20 mg/kg of body weight.

Home infusion

Your doctor may consider that you can have home infusion of Nexviadyme if it is safe and convenient to do so. If you get any side effects during an infusion of Nexviadyme, your home infusion staff member may stop the infusion and start appropriate medical treatment.

Instructions for proper use

Nexviadyme is given through a drip into a vein (intravenous infusion). It is supplied to the healthcare professional as a powder to mix with sterile water and further dilute with glucose before infusing it.

If you are given more Nexviadyme than you should

Excessive infusion rate of Nexviadyme may result in hot flush.

If you miss your dose of Nexviadyme

If you have missed an infusion, please contact your doctor. If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

If you stop using Nexviadyme

Speak to your doctor if you wish to stop Nexviadyme treatment. The symptoms of your disease may worsen if you stop treatment.

4. Possible side effects

Side effects mainly occur while patients are being given Nexviadyme infusion or shortly afterwards. You must tell your doctor immediately if you get an infusion-associated reaction or an allergic reaction. Your doctor may give you medicines before your infusion to prevent these reactions.

Infusion-associated reactions

Mostly infusion-associated reactions are mild or moderate. Symptoms of infusion-associated reaction include:

  • chest discomfort
  • increased blood pressure
  • increased heart rate
  • chills
  • cough
  • diarrhoea
  • fatigue
  • headache
  • flu-like illness
  • nausea
  • vomiting
  • red eye
  • pain in arms and legs
  • skin redness
  • itchy skin
  • rash
  • hives.

Allergic reactions

Allergic reactions may include symptoms such as:

  • difficulty breathing
  • chest pressure
  • flushing
  • cough
  • dizziness
  • nausea
  • redness on palms and feet
  • itchy palms and feet
  • swollen lower lip and tongue
  • low levels of oxygen in the blood
  • rash.

Very common (may affect more than 1 in 10 people)

  • Hypersensitivity
  • Headache
  • Nausea
  • Itchy skin
  • Rash

Common (may affect up to 1 in 10 people)

  • Severe allergic reaction (anaphylaxis)
  • Dizziness
  • Sleepiness
  • Shaking
  • Burning sensation
  • Red eyes
  • Itchy eyes
  • Swelling of eyelid
  • Rapid heartbeat
  • Flushing
  • Raised blood pressure
  • Low blood pressure
  • Skin and lips turning blue
  • Hot flush
  • Pale skin
  • Cough
  • Difficulty breathing
  • Throat irritation
  • Mouth and throat pain
  • Diarrhoea
  • Vomiting
  • Lip swelling
  • Swollen tongue
  • Abdominal (belly) pain
  • Abdominal (belly) pain upper
  • Indigestion
  • Itchy, lumpy rash (hives)
  • Redness of hands
  • Redness of skin
  • Red rash
  • Excessive sweating
  • Itchy rash
  • Skin plaque
  • Muscle spasms
  • Muscle aches
  • Pain in arm or leg
  • Flank pain
  • Fatigue
  • Chills
  • Fever
  • Chest discomfort
  • Pain
  • Flu-like illness
  • Infusion site pain
  • Low blood oxygen
  • Weakness
  • Swelling of face
  • Feeling cold or hot

Uncommon (may affect up to 1 in 100 people)

  • Inflammation of eyes
  • Numbness or tingling
  • Watery eyes
  • Extra heart beats
  • Rapid breathing
  • Swelling of throat
  • Numbness in the mouth, tongue, or lip
  • Tingling in the mouth, tongue, or lip
  • Difficulty swallowing
  • Swelling of skin
  • Skin discolouration
  • Facial pain
  • Increased body temperature
  • Infusion site tissue leakage
  • Infusion site joint pain
  • Infusion site rash
  • Infusion site reaction
  • Infusion site itching
  • Localised swelling
  • Swelling in the arms and legs
  • Wheezing
  • Blood test for inflammation
  • Reduced sensation to touch, pain, and temperature
  • Oral discomfort (including lip burning sensation)

The reported side effects seen in children and adolescents were similar to those seen in adults.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine

5. How to store Nexviadyme

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Unopened vials:

Store in a refrigerator (2°C - 8°C).

Reconstituted solution:

After reconstitution, immediate use for dilution is recommended. The reconstituted solution can be stored up to 24 hours when refrigerated at 2°C to 8°C.

Diluted solution:

After dilution, immediate use is recommended. The diluted solution can be stored for 24 hours at 2°C to 8°C followed by 9 hours at room temperature (up to 25°C).

Do not throw away any medicines via wastewater or household waste. Ask your doctor, pharmacist, or nurse how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Nexviadyme contains

The active substance is avalglucosidase alfa. One vial contains 100 mg of avalglucosidase alfa. After reconstitution, the solution contains 10 mg of avalglucosidase alfa per ml and after dilution the concentration varies from 0.5 mg/ml to 4 mg/ml.

The other ingredients are

  • Histidine
  • Histidine hydrochloride monohydrate
  • Glycine
  • Mannitol
  • Polysorbate 80

What Nexviadyme looks like and contents of the pack

Avalglucosidase alfa is a powder for concentrate for solution for infusion in a vial (100 mg/vial). Each pack contains 1, 5, 10, or 25 vials. Not all pack sizes may be marketed.

The powder is white to pale yellow. After reconstitution it is a clear, colourless to pale yellow solution. The reconstituted solution must be further diluted.

Marketing Authorisation Holder
Sanofi
410 Thames Valley Park Drive
Reading
Berkshire
RG6 1PT
UK
Tel: 0800 035 2525
email: [email protected]

Manufacturer
Genzyme Ireland Limited
IDA Industrial Park
Old Kilmeaden Road
Waterford
Ireland

This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor, nurse or pharmacist.

This leaflet was last revised in December 2023.

© Sanofi

904577

SANOFI
Company image
Address
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0)800 035 2525
Telephone
+44 (0)118 354 3000